Nonsteroidal Anti-inflammatory Drugs-sparing Effect of Symptomatic Slow-acting Drugs for Osteoarthritis in Knee Osteoarthritis Patients
10.4078/jrd.2019.26.3.179
- Author:
Soo Kyung CHO
1
;
Hyoungyoung KIM
;
Ha Rim PARK
;
Wooseok CHOI
;
Seongmi CHOI
;
Sun Young JUNG
;
Eun Jin JANG
;
Yoon Kyoung SUNG
Author Information
1. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. sungyk@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Osteoarthritis;
Symptomatic slow-acting drugs for osteoarthritis;
Nonsteroidal anti-inflammatory drugs
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
Cohort Studies;
Comorbidity;
Data Collection;
Humans;
Injections, Intra-Articular;
Knee;
Osteoarthritis;
Osteoarthritis, Knee;
Referral and Consultation;
Retrospective Studies
- From:Journal of Rheumatic Diseases
2019;26(3):179-185
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the nonsteroidal anti-inflammatory drugs (NSAID)-sparing effect of symptomatic slow-acting drugs for osteoarthritis (SYSADOA) in knee osteoarthritis (OA) patients. METHODS: A retrospective study was conducted on a cohort of knee OA patients who visited a single academic referral hospital from 2013 to 2014. Among all patients, NSAID users in their first visit were extracted and divided into SYSADOA users and SYSADOA non-users. All patients were observed from their first visit with knee OA to their last visit, NSAID discontinuation, or the date of data collection, July 2017 (mean observational periods: 369.1 days). To evaluate the NSAID-sparing effect of SYSADOA, Cox regression analysis was performed after adjusting for confounding factors. RESULTS: Patients for this study (n=212) were divided into SYSADOA users (n=57) and SYSADOA non-users (n=155). The mean age (68.8 vs. 66.6 years old, p=0.31) and the number of comorbidities (p=0.73) were comparable between the two groups. The SYSADOA users showed higher Kellgren–Lawrence (KL) grade (66.7% of patients with more than KL grade 3) than SYSADOA non-users (42.6% of patients with more than KL grade 3) (p=0.02). In treatment, the frequency of intra-articular injection was higher in the SYSADOA user group than the SYSADOA non-user group (33.3% vs. 9.0%, p<0.01). In Cox regression analysis, SYSADOA use contributed to NSAID discontinuation in knee OA patients (hazard ratio 2.97, 95% confidential interval 1.42∼6.22). CONCLUSION: This real-world analysis demonstrated that SYSADOA use combined with NSAIDs had a significant effect on NSAID discontinuation in patients with knee OA.
